PET GRIFFIN
Research type
Research Study
Full title
In vivo Gastrin Releasing Peptide Receptor quantification using PET CT in a variety of neoplasms; a histological correlate study
IRAS ID
318245
Contact name
Ashley Groves
Contact email
Sponsor organisation
University College London Hospitals Foundation Trust
Duration of Study in the UK
2 years, 6 months, 30 days
Research summary
The gastrin-releasing peptide receptor (GRPR) is a G protein-coupled receptor whose endogenous ligand is a gastrin-releasing peptide. In humans, it is highly expressed in the pancreas and is also expressed in the stomach, adrenal cortex, and brain. Physiologically it performs several recognized functions. Gastrin-releasing peptide (GRP) regulates numerous functions of the gastrointestinal and central nervous systems, including the release of gastrointestinal hormones, smooth muscle cell contraction, angiogenesis, and epithelial cell proliferation. Pathologically (GRPR) it is a potent mitogen for neoplastic tissues and the receptor is aberrantly expressed in numerous cancers such as those of the lung, colon, and prostate. This oncological overexpression creates an exciting potential target for molecular radiotherapy in a number of cancers that have currently a poor prognosis.
In this study we will look to correlate the expression of GRPR on a variety of neoplasms with the uptake of a novel radioisotope PET ligand (Ga68 NeoB) in order to assess the potential use of this receptor as a target for molecular radiotherapy. This research will be conducted by recruiting participants from UCLH and other local hospitals in patients with both primary and metastatic carcinoma in four cancer types.
REC name
South Central - Oxford B Research Ethics Committee
REC reference
24/SC/0079
Date of REC Opinion
2 May 2024
REC opinion
Further Information Favourable Opinion